Journal of Clinical Psychiatry
Psychedelic therapy appeared associated with large acute and sustained reductions in suicidality, according to results of a meta-analysis published in the Journal of Clinical Psychiatry.
The study’s authors aimed to fill a knowledge gap regarding psychedelic therapy and effects on suicidality. “Suicide is a global health concern and innovative interventions that target suicidality are needed,” they wrote.
World Journal Psychiatry
This literature review analyzes possible mechanisms of action for ketamine as an antidepressant. Traditional antidepressants often take weeks to months to work and are not effective for all patients. This review specifically compares the effects of serotonergic psychedelics with other antidepressants on plasticity at multiple levels of nervous system functioning.
Journal of Psychoactive Drugs
Read one of the first studies on the emerging Ketamine-Assisted Psychotherapy model as it compares to the medical model of the Ketamine Infusion Clinic. One of the most interesting contentions between the two models is that Ketamine-Assisted Psychotherapy maintains that the psychedelic experience itself is an irreducible catalyst for the antidepressant effects of ketamine, while the Ketamine Infusion Clinic seeks to minimize the psychedelic experience (by controlling dose over time), seeking instead to get the antidepressant effect without the psychedelic experience.
These MDMA, psilocybin, LSD, DMT and ketamine clinical trials may have huge impacts on the entire psychedelic medicine industry.
By Emily Witt, The New Yorker
The mind-altering drug Ketamine has been shown to help people suffering from anxiety and depression. But how it helps, who it will serve, and who will profit are open questions.